摘要
目的临床观察胰岛素增敏剂吡格列酮对2型糖尿病合并非酒精性脂肪肝炎患者治疗的有效性和安全性。方法将55例2型糖尿病合并非酒精性脂肪肝炎患者随机分为两组,吡格列酮组给予吡格列酮30 mg,1次/d,对照组给予除噻唑烷二酮类以外的其他降糖药物治疗,疗程均为24周。比较两组治疗前后指标:空腹血糖、餐后2 h血糖、空腹胰岛素、糖化血红蛋白、胰岛素抵抗指数、天冬氨酸转氨酶、丙氨酸转氨酶、血脂及脂肪肝程度。结果治疗后两组空腹血糖、餐后2 h血糖、糖化血红蛋白均有明显改善,两组比较差异无统计学意义(P>0.05),吡格列酮组在控制空腹血胰岛素、胰岛素抵抗指数水平及改善肝功能、血脂、脂肪肝程度方面,与对照组相比差异均有统计学意义(P<0.05)。结论吡格列酮能增加胰岛素敏感性,在血糖下降的同时,可明显改善肝酶学的异常,胰岛素抵抗和减轻脂肪肝的程度。
Objective To observe the efficacy and adverse drug reactions of pioglitazone in treatment of non-alcoholic steatohepatitis（NASH） with type 2 diabetes mellitus.Methods Fifty five patients with NASH were randomly divided into two groups：pioglitazone group with pioglitazone 30 mg per day,while control group with Hypoglycemic drug except for thiazolidine dione and Biguanides,the period of treatment was 24 weeks.Fasting blood glucose,2-hour postprandial blood glucose,fasting blood insulin,glycosylated hemoglobin,insulin resistance index,alanine aminotransferase,aspartate aminotransferase blood lipid and the degree of fatty liver were measured before and after the treatment.Results Both the two groups significantly reduced fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin after treatment,but there were not significant differences in two groups（P0.05）.Compared with the patients in control group,Pioglitazone group had significant differences in lower fasting blood insulin and insulin resistance index,improvement liver function and blood lipid,modification the degree of fatty liver（P0.05）.Conclusion Pioglitazone can increase insulin sensitivity,improve the abnormalities of enzyme tests,reduce insulin resistance and improve the fatty liver.
出处
《中华全科医学》
2011年第6期895-895,916,共2页
Chinese Journal of General Practice
关键词
2型糖尿病
脂肪肝
肝炎
吡格列酮
Type 2 diabetes mellitus
Fatty liver
Hepatitis
Pioglitazone
